Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022

Published on March 17, 2022

This report describes vaccination with a primary series of the Pfizer-BioNTech mRNA COVID-19 vaccine as effective in protecting against Omicron infection among children and adolescents.

Continue reading on website
Other news

EARLY RELEASE: Hospitalization of Infants and Children Aged 0-4 Years with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 2020-February 2022

March 15, 2022
This report describes COVID-19 hospitalization rates among infants and children aged 0-4 years, including during Omicron variant predominance.

EARLY RELEASE: COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022

March 18, 2022
This report describes adult COVID-19 hospitalization rates by race/ethnicity during SARS-CoV-2 Delta and Omicron predominance.